RNS Number : 9567P
The MedicX Fund Limited
01 April 2009
 



 


THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICACANADAAUSTRALIA OR JAPAN



For Immediate Release  

   1 April 2009

MedicX Fund Limited

("MedicX Fund", "the Fund" or "the Company")


Proposed Placing and Offer for subscription of up to 75,000,000 new Ordinary Shares


Terms and Conditions of the Placing 


IMPORTANT INFORMATION FOR PLACEES ONLY

 

MEMBERS OF THE PUBLIC ARE NOT ELIGIBLE TO TAKE PART IN THE PLACING. THIS DOCUMENT AND THE TERMS AND CONDITIONS SET OUT AND REFERRED TO HEREIN ARE DIRECTED ONLY AT PERSONS SELECTED BY COLLINS STEWART EUROPE LIMITED ("COLLINS STEWART" AND THE "PLACING AGENT") WHO ARE "INVESTMENT PROFESSIONALS" FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (THE "FPO") OR "HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS ETC" FALLING WITHIN ARTICLE 49(2) OF THE FPO OR TO PERSONS TO WHOM IT MAY OTHERWISE LAWFULLY BE COMMUNICATED (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS "RELEVANT PERSONS"). THIS DOCUMENT AND THE TERMS AND CONDITIONS SET OUT HEREIN MUST NOT BE ACTED ON OR RELIED ON BY PERSONS WHO ARE NOT RELEVANT PERSONS.


THE NEW ORDINARY SHARES THAT ARE THE SUBJECT OF THE PLACING (THE "PLACING SHARES") ARE NOT BEING OFFERED OR SOLD TO ANY PERSON IN THE EUROPEAN UNION, OTHER THAN TO "QUALIFIED INVESTORS" AS DEFINED IN ARTICLE 2.1(E) OF DIRECTIVE 2003/71/EC (THE "PROSPECTUS DIRECTIVE"), WHICH INCLUDES LEGAL ENTITIES WHICH ARE REGULATED BY THE FINANCIAL SERVICES AUTHORITY (THE "FSA") OR ENTITIES WHICH ARE NOT SO REGULATED WHOSE CORPORATE PURPOSE IS SOLELY TO INVEST IN SECURITIES.


The Placing Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act") or under the securities laws of any state or other jurisdiction of the United States and may not be offered, sold, resold or delivered, directly or indirectly, in or into the United States absent registration except pursuant to an exemption from or in a transaction not subject to the registration requirements of the Securities Act. No public offering of the Placing Shares is being made in the United States. The Placing (as defined below) is being made outside the United States in offshore transactions (as defined in Regulation S under the Securities Act ("Regulation S")) meeting the requirements of Regulation S under the Securities Act. Persons receiving this document (including custodians, nominees and trustees) must not forward, distribute, mail or otherwise transmit it in or into the United States or use the United States mails, directly or indirectly, in connection with the Placing.


This document does not constitute an offer to sell or issue or a solicitation of an offer to buy or subscribe for Placing Shares in any jurisdiction including, without limitation, the United States, Canada, Australia, Japan or any other jurisdiction in which such offer or solicitation is or may be unlawful (a "Prohibited Jurisdiction"). This document and the information contained herein are not for publication or distribution, directly or indirectly, to persons in a Prohibited Jurisdiction unless permitted pursuant to an exemption under the relevant local law or regulation in any such jurisdiction.


The distribution of this document, the Placing and/or issue of the Placing Shares in certain jurisdictions may be restricted by law and/or regulation. No action has been taken by MedicX Fund Limited (the "Company"), the Placing Agent or any of its Affiliates (as defined below) that would permit an offer of the Placing Shares or possession or distribution of this document or any other publicity material relating to such Placing Shares in any jurisdiction where action for that purpose is required. Persons receiving this document are required to inform themselves about and to observe any such restrictions.


Collins Stewart, which is authorised and regulated by the Financial Services Authority, is acting for the Company and for no one else in connection with the Placing and will not be responsible to anyone other than the Company for providing the protections afforded to clients of Collins Stewart or for affording advice in relation to the Placing, or any other matters referred to herein.


By participating in the Placing (as defined below), each person who is invited to and who chooses to participate in the Placing (a "Placee") by making an oral offer to take up Placing Shares is deemed to have read and understood this document in its entirety and to be providing the representations, warranties, undertakings, agreements and acknowledgements contained herein.


Details of the Placing Agreement and the Placing Shares


The Company, MedicX Adviser Ltd (the "Investment Adviser") and MedicX Holdings Ltd have entered into a placing agreement (the "Placing Agreement") with Collins Stewart, under which the Placing Agent has, subject to the terms set out therein, agreed to use its reasonable endeavours, as agent of the Company, to procure Placees for the Placing Shares (the "Placing").


The Placing Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with each other and the Company's existing Ordinary Shares then in issue including the right to receive all dividends and other distributions declared, made or paid in respect of such Ordinary Shares after the date of issue.


The Placing Shares will be issued free of any pre-emption rights, encumbrance, lien or other security interest.


Application for listing and admission to trading


Application will be made to the FSA as the competent authority for listing for admission of the new Ordinary Shares to the Official List maintained by the FSA in accordance with section 74(1) of the Financial Services and Markets Act 2000 ("FSMA") for the purposes of part VI of FSMA and to the London Stock Exchange plc (the "London Stock Exchange") for admission to trading of the new Ordinary Shares on the London Stock Exchange's market for listed securities ("Admission"). It is expected that Admission will become effective and that dealings will commence on 8 April 2009, and in any event no later than 15 May 2009.


Participation in, and principal terms of, the Placing


A single price (the "Placing Price") will be payable to the Placing Agent by all Placees.


Prospective Placees will be identified and contacted by the Placing Agent.


The Placing is expected to close at noon on 3 April 2009. However, the Company may, with the prior approval of Collins Stewart, bring forward or postpone this date. In the event such date is changed, the Company will notify investors who have applied for new Ordinary Shares either by post, by electronic mail or by the publication of a notice through a regulatory information service provider to the London Stock Exchange.


Collins Stewart will re-contact and confirm orally to Placees the size of their respective allocations and a trade confirmation will be dispatched as soon as possible thereafter. Collins Stewart's oral confirmation of the size of allocations and each Placee's oral commitments to accept the same will constitute a legally binding agreement pursuant to which each such Placee will be required to accept the number of Placing Shares allocated to the Placee at the Placing Price and otherwise on the terms and subject to the conditions set out herein and the Prospectus.


The Placing Agent (after consulting with the Company and the Investment Adviser) reserves the right to scale back the number of Placing Shares to be subscribed by any Placee. The Company and the Placing Agent also reserve the right not to accept offers to subscribe for Placing Shares or to accept such offers in part rather than in whole. The Placing Agent shall be entitled to effect the Placing by such method as it shall in its sole discretion determine. To the fullest extent permissible by law, neither the Placing Agent, any holding company thereof, nor any subsidiary, branch or affiliate of the Placing Agent (each an "Affiliate") nor any person acting on its behalf shall have any liability to Placees (or to any other person whether acting on behalf of a Placee or otherwise). In particular, neither of the Placing Agent, nor any Affiliate thereof nor any person acting on its behalf shall have any liability to Placees in respect of its conduct of the Placing. No commissions will be paid to Placees or directly by Placees in respect of any Placing Shares.


Each Placee's obligations will be owed to the Company and to the Placing Agent. Following the oral confirmation referred to above, each Placee will also have an immediate, separate, irrevocable and binding obligation, owed to the Placing Agent, to pay to the Placing Agent (or as the Placing Agent may direct) in cleared funds an amount equal to the product of the Placing Price and the number of Placing Shares such Placee has agreed to acquire. The Company shall allot such Placing Shares to each Placee following each Placee's payment to the Placing Agent of such amount.


All obligations of the Placing Agent under the Placing will be subject to fulfilment of the conditions referred to below under "Conditions of the Placing".


Conditions of the Placing


The Placing is conditional upon the Placing Agreement becoming unconditional and not having been terminated in accordance with its terms.


The obligations of the Placing Agent under the Placing Agreement (which are several obligations) are conditional, inter alia, on:

 

1. admission occurring by no later than 8 April 2009 (or such later date as may be agreed between the Company and the Placing Agent, not being later than 15 May 2009);

 

2. the Company and the Investment Adviser delivering, by no later than 5.00 p.m. on the business day prior to Admission, to the Placing Agent certificates confirming, inter alia, that none of the representations, warranties and undertakings given by the Company or the Investment Adviser, respectively, in the Placing Agreement has been breached or was untrue, inaccurate or misleading when made or would cease to be true and accurate were it to be repeated by reference to the facts subsisting on the date of the certificates; and

 

3. minimum net proceeds of £15 million being raised under the Placing and Offer for Subscription (or such lower amount as shall be agreed between the Company, the Investment Adviser and Collins Stewart).


If (a) the conditions are not fulfilled (or to the extent permitted under the Placing Agreement waived by the Placing Agent), or (b) the Placing Agreement is terminated in the circumstances specified below, the Placing will lapse and each Placee's rights and obligations hereunder shall cease and determine at such time and no claim may be made by a Placee in respect thereof. The Placing Agent shall not have any liability to any Placee (or to any other person whether acting on behalf of a Placee or otherwise) in respect of any decision it may make as to whether or not to waive or to extend the time and/or date for the satisfaction of any condition in the Placing Agreement or in respect of the Placing generally.


By participating in the Placing, each Placee agrees that its rights and obligations hereunder terminate only in the circumstances described above and under "Right to terminate under the Placing Agreement" below, and will not be capable of rescission or termination by the Placee.


Right to terminate under the Placing Agreement


Collins Stewart may, at any time before Admission, terminate the Placing Agreement by giving notice to the Company if:


a) any statement contained in the Prospectus is or has become untrue, incorrect in any material respect or misleading in any material respect; or


b) matters have arisen which would, if the Prospectus were issued at that time, constitute a material omission therefrom; or


c) There has been a breach of any of the warranties which is material in the context of the Placing and Offer for Subscription (the "Issue"); or


d) one or more of the warranties was untrue or inaccurate in a manner which was material in the context of the Issue when given or, by reason of any event occurring or circumstance arising after the date hereof, any one or more of the warranties would cease to be true and accurate in a manner which is material in the context of the Issue if repeated at that time; or


e) by reason of any event occurring or circumstance arising after the date hereof the Company or the Investment Adviser would have been in material breach of the warranties if given at the time such event occurred or circumstance arose; or


f) the Company or the Investment Adviser has failed to comply with any material obligation under the Placing Agreement or otherwise relating to the Issue.


By participating in the Placing, each Placee agrees with Collins Stewart that the exercise by Collins Stewart of any right of termination or other discretion under the Placing Agreement shall be within the absolute discretion of Collins Stewart and that Collins Stewart need not make any reference to the Placee in this regard and that, to the fullest extent permitted by law, Collins Stewart shall not have any liability whatsoever to the Placee in connection with any such exercise.


Prospectus


The Prospectus has been published in connection with the Placing and Admission. The Prospectus has been approved by the UK Listing Authority. A Placee may only rely on the information contained in the Prospectus in deciding whether or not to participate in the Placing.


Each Placee, by accepting a participation in the Placing, agrees that the content of this document and the Prospectus is exclusively the responsibility of the Company and confirms to the Placing Agent and the Company that it has neither received nor relied on any information, representation, warranty or statement made by or on behalf of the Placing Agent (other than the amount of the relevant Placing participation in the oral confirmation given to Placees and the trade confirmation referred to below), any of its Affiliates, any persons acting on its behalf or the Company other than the Prospectus and neither the Placing Agent, nor any of its Affiliates, nor any persons acting on its behalf nor the Company will be liable for the decision of any Placee to participate in the Placing based on any other information, representation, warranty or statement which the Placee may have obtained or received (regardless of whether or not such information, representation, warranty or statement was given or made by or on behalf of any such persons) other than the Prospectus. By participating in the Placing, each Placee acknowledges and agrees, to the Placing Agent for itself and as agent for the Company, that, except in relation to the information contained in this document and the Prospectus, it has relied on its own investigation of the business, financial or other position of the Company in deciding to participate in the Placing. Nothing in this paragraph shall exclude the liability of any person for fraudulent misrepresentation.


Registration and settlement


Settlement of transactions in the Placing Shares (ISIN GG00B1DVQL92) following Admission will take place within the CREST system, using the DVP mechanism, subject to certain exceptions. The Placing Agent reserves the right to require settlement for and delivery of the Placing Shares to Placees by such other means that it deems necessary, if delivery or settlement is not possible or practicable within the CREST system within the timetable set out in this document or would not be consistent with the regulatory requirements in the Placee's jurisdiction.


Each Placee allocated Placing Shares in the Placing will be sent a trade confirmation stating the number of Placing Shares allocated to it, the Placing Price, the aggregate amount owed by such Placee to Collins Stewart and settlement instructions. Placees should settle against CREST ID: 288. It is expected that such trade confirmation will be despatched on 3 April 2009 and that this will also be the trade date. Each Placee agrees that it will do all things necessary to ensure that delivery and payment is completed in accordance with either the standing CREST or certificated settlement instructions which it has in place with the Placing Agent.


It is expected that settlement will be on 8 April 2009 on a T+3 basis in accordance with the instructions set out in the trade confirmation.


Interest is chargeable daily on payments not received from Placees on the due date in accordance with the arrangements set out above at the rate of 2 percentage points above the base rate of Barclays Bank Plc.


Each Placee is deemed to agree that if it does not comply with these obligations, the Placing Agent may sell any or all of the Placing Shares allocated to the Placee on such Placee's behalf and retain from the proceeds, for its own account and profit, an amount equal to the aggregate amount owed by the Placee plus any interest due. The Placee will, however, remain liable for any shortfall below the aggregate amount owed by such Placee and it may be required to bear any stamp duty or stamp duty reserve tax (together with any interest or penalties) which may arise upon the sale of such Placing Shares on such Placee's behalf.


If Placing Shares are to be delivered to a custodian or settlement agent, the Placee should ensure that the trade confirmation is copied and delivered immediately to the relevant person within that organisation.


Insofar as Placing Shares are registered in the Placee's name or that of its nominee or in the name of any person for whom the Placee is contracting as agent or that of a nominee for such person, such Placing Shares will, subject as provided below, be so registered free from any liability to PTM levy, stamp duty or stamp duty reserve tax. If there are any circumstances in which any other stamp duty or stamp duty reserve tax is payable in respect of the issue of the Placing Shares, neither Collins Stewart nor the Company shall be responsible for the payment thereof. Placees will not be entitled to receive any fee or commission in connection with the Placing.


Representations and Warranties


By participating in the Placing, each Placee (and any person acting on such Placee's behalf):



The acknowledgements, agreements, undertakings, representations and warranties referred to above are given to each of the Company and the Placing Agent (for its own benefit and, where relevant, the benefit of its Affiliates and any person acting on its behalf) and are irrevocable.


No UK stamp duty or stamp duty reserve tax should be payable to the extent that the Placing Shares are issued or transferred (as the case may be) into CREST to, or to the nominee of, a Placee who holds those shares beneficially (and not as agent or nominee for any other person) within the CREST system and registered in the name of such Placee or such Placee's nominee.


Any arrangements to issue or transfer the Placing Shares into a depositary receipts system or a clearance service or to hold the Placing Shares as agent or nominee of a person to whom a depositary receipt may be issued or who will hold the Placing Shares in a clearance service, or any arrangements subsequently to transfer the Placing Shares, may give rise to stamp duty and/or stamp duty reserve tax, for which neither the Company nor Collins Stewart will be responsible and the Placee to whom (or on behalf of whom, or in respect of the person for whom it is participating in the Placing as an agent or nominee) the allocation, allotment, issue or delivery of Placing Shares has given rise to such stamp duty or stamp duty reserve tax undertakes to pay such stamp duty or stamp duty reserve tax forthwith and to indemnify on an after-tax basis and to hold harmless the Company and Collins Stewart in the event that any of the Company and/or Collins Stewart has incurred any such liability to stamp duty or stamp duty reserve tax.


In addition, Placees should note that they will be liable for any capital duty, stamp duty and all other stamp, issue, securities, transfer, registration, documentary or other duties or taxes (including any interest, fines or penalties relating thereto) payable outside the UK by them or any other person on the acquisition by them of any Placing Shares or the agreement by them to acquire any Placing Shares.


All times and dates in this document may be subject to amendment. the Placing Agent shall notify the Placees and any person acting on behalf of the Placees of any such changes.


This document has been issued by the Company and is the sole responsibility of the Company.


The rights and remedies of Collins Stewart and the Company under these terms and conditions are in addition to any rights and remedies which would otherwise be available to each of them and the exercise or partial exercise or partial exercise of one will not prevent the exercise of others.


Each Placee may be asked to disclose in writing or orally to Collins Stewart:

 

(a) if he is an individual, his nationality; or 

 

(b) if he is a discretionary fund manager, the jurisdiction in which the funds are managed or owned.



For further information please contact:


MedicX Fund                                                        +44 (0) 1481 723 450

David Staples, Chairman


MedicX Group                                                       +44 (0) 0808 2025461

Keith Maddin, Chairman

Mike Adams, Managing Director


Buchanan Communications                                      +44 (0) 20 7466 5000

Charles Ryland/Mary-Jane Johnson/Miranda Higham


Collins Stewart Europe Limited

Robbie Robertson/Andrew Zychowski/Helen Goldsmith    +44 (0) 20 7523 8000


This information is provided by RNS
The company news service from the London Stock Exchange
 
 
 

RNS news service provided by Hemscott Group Limited.